Summary
Drug manufacturers are beginning to explore new contract models to support industrywide calls for value-based-care reform.
New trends in value-based pharmaceutical contracting are emerging. Win-win negotiations require the right drug, the right outcome, and the right data sharing agreement.
Cardiology, infectious disease, and oncology are the leading high-impact areas where health insurers are finding success.
Log in to continue reading
Client log in
Welcome back. Log in to your account to continue reading this research.
Become a client
Become a client today for these benefits:
- Stay ahead of changing market and customer dynamics with the latest insights.
- Partner with expert analysts to make progress on your top initiatives.
- Get answers from trusted research using Izola, Forrester's genAI tool.
Purchase this report
This report is available for individual purchase ($1495).